Andy C. Rawstron
St, Ls9, 7TF
Leeds, ENG, United Kingdom
Leeds, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study.
Journal: The Lancet. Rheumatology
Published: April 11, 2026
High-sensitivity flow cytometry in rheumatoid arthritis shows that early B-cell subset depletion is linked to 5-year rituximab response, while failure to deplete B cells occurs early in subsequent poly-refractory disease.
Journal: Annals of the rheumatic diseases
Published: April 10, 2026
COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network.
Journal: British journal of haematology
Published: July 17, 2025
Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK's Haematological Malignancy Research Network.
Journal: Haematologica
Published: January 04, 2025
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.
Journal: Bone marrow transplantation
Published: August 01, 2023
Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
Journal: EBioMedicine
Published: July 17, 2022
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
Journal: British journal of haematology
Published: April 30, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 04, 2022
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.
Journal: Frontiers in immunology
Published: October 27, 2021
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Journal: British journal of haematology
Published: May 24, 2021
Last Updated: 09/26/2026